Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

A number of other brokerages have also weighed in on APTO. Alliance Global Partners upgraded shares of Aptose Biosciences to a “strong-buy” rating in a report on Thursday, February 27th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Aptose Biosciences in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Aptose Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $130.00.

Aptose Biosciences Stock Up 15.1 %

Shares of NASDAQ APTO opened at $2.98 on Wednesday. Aptose Biosciences has a twelve month low of $2.39 and a twelve month high of $54.56. The firm has a market cap of $6.38 million, a P/E ratio of -1.00 and a beta of 0.88. The company has a 50 day moving average of $5.64 and a 200 day moving average of $8.54.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp boosted its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the period. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. 26.62% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.